When someone loses weight, the scale doesn’t say which tissues changed. Researchers can estimate fat and lean mass separately, and they’re studying whether additional treatments might help preserve lean tissue during medication-assisted weight loss.
One such study tested bimagrumab with semaglutide. It offers an interesting look at body composition, but it also illustrates an important distinction: preserving lean mass on a scan is not the same as proving better strength.
Why look beyond total weight?
Lean mass is a broad measurement. It includes muscle along with other tissues and body water. A body-composition scan can help researchers estimate changes, but it doesn’t directly measure how much someone can lift, how quickly they can stand from a chair or how they feel walking upstairs.
Those other measures matter because the goal for many people is not simply a lower number. It may be moving comfortably, keeping up with work or family, or feeling able to do everyday tasks.
Our article on GLP-1 research and body composition explains the differences among fat mass, lean mass and strength.
What was tested?
In a phase 2 trial called BELIEVE, 507 adults with obesity or overweight and a related condition were assigned to nine groups. The study excluded people with diabetes. The groups received bimagrumab, semaglutide, combinations of the two or placebo during the main 48-week period. Some participants continued into an extension.
Bimagrumab is an antibody that targets a pathway researchers are investigating in relation to muscle and fat. Semaglutide works through a GLP-1 pathway. The purpose of the trial was to compare what happened with each approach and with the combination.
This is a study of a specific research treatment, not an indication that it is offered by Fresh Day or that people should combine treatments themselves.
What did the scans show?
Researchers used DXA body-composition measurements. The combination groups had smaller average reductions in lean mass than the semaglutide-only groups, while fat mass also changed.
That result helps answer a body-composition question in the trial. It doesn’t mean nobody lost lean mass, and it doesn’t show that every person using semaglutide would have the same change without an additional treatment.
Researchers also collected patient-reported physical-function information. A questionnaire about function and a scan each offer useful information, but neither should be casually relabeled as a direct test of muscle strength.
What about unwanted effects?
The researchers tracked adverse events and discontinuations. Muscle spasms, diarrhea and acne were among the commonly reported effects with bimagrumab; digestive effects were also reported with semaglutide. Some participants stopped treatment because of adverse events.
Those details matter when considering any potential benefit. A change in a scan is only one part of the balance between effectiveness, comfort and safety.
What can you do with this information now?
If you’re concerned about losing strength while taking a weight-management medicine, describe what you notice to your care team. Perhaps carrying groceries feels harder, you’re unusually tired or your appetite has dropped enough that meals are difficult. Those details can guide a useful review.
Appropriate resistance activity and adequate nourishment are topics to discuss with your clinician or dietitian. The right plan depends on your health, current activity, food intake and any symptoms. A hard workout or a supplement isn’t required to prove that you’re taking the concern seriously.
Keep the research question precise
The combination trial suggests one possible approach to body composition deserves continued study. It does not make a scan result a guarantee of better everyday function.
Look for future studies that measure strength and activities people care about, follow participants for longer and report unwanted effects clearly. In the meantime, your own day-to-day function is worth bringing into routine follow-up.